Css LLC Mirati Therapeutics, Inc. Transaction History

Css LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$41.99 - $62.38 $14.4 Million - $21.4 Million	343,845 New	343,845 $20.2 Million
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $178,500 - $260,100	3,000 Added 39.47%	10,600 $740,000
Q2 2022 Aug 15, 2022	BUY	$39.16 - $88.71 $255,362 - $578,477	6,521 Added 604.36%	7,600 $510,000
Q2 2021 Aug 16, 2021	SELL	$144.0 - $179.73 $259,200 - $323,514	-1,800 Reduced 62.52%	1,079 $174,000
Q1 2021 May 17, 2021	BUY	$158.92 - $221.61 $457,530 - $638,015	2,879 New	2,879 $493,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Css LLC, based on Form 13F filings with the SEC.

Stay updated on Css LLC with notifications on news.